Probiotics Show Promise In Treating Gastrointestinal Diseases
Main Category: MRSA / Drug ResistanceAlso Included In: Infectious Diseases / Bacteria / Viruses; GastroIntestinal / Gastroenterology; Nutrition / Diet
Article Date: 08 May 2006 - 0:00 PDT
| Patient / Public: | ![]() |
4.75 (4 votes) |
| Healthcare Prof: | ![]() |
4.75 (4 votes) |
Current interest in probiotics is motivated not only by the clinical data showing the efficacy of some probiotic bacteria, but also by the increasing antibiotic resistance of pathogenic bacteria (particularly in hospitals) and the rise of consumers' demand for natural substitutes of drugs.
Among probiotic applications, reduction of diarrhea is probably the best-documented effect confirmed by recent meta-analyses. Research on Helicobacter pylori indicates that probiotics are unable to eradicate the infection, but could be useful in decreasing infection levels and as adjuvants of therapy-associated side effects. Studies performed in inflammatory bowel disease suggest that high doses of probiotics and most likely a combination of different lactobacilli and bifidobacteria are more effective in decreasing inflammatory score and maintaining patients in remission than a single probiotic strain. Probiotic studies evaluating amelioration of symptoms in irritable bowel syndrome would require more sustained patient numbers, but the efficacy seems to be strain-dependent. Not enough probiotic intervention trials have been reported on colon cancer to allow any firm conclusion.
Few randomized, double-blind placebo-controlled human trials are available, and some involved only small numbers of patients. They are difficult to compare because of the differences in probiotic strains employed, doses and formulation. However, the accumulated data is encouraging.
About the S. KARGER AG
With over a century of experience in connecting the world of biomedical science, Karger publishes nearly 80 scientific, peer-reviewed journals and 150 serial and non-serial books and supplement issues annually for a global scientific readership.
S. KARGER AG
Allschwilerstrasse 10,
P.O Box,
CH-4009 Basel,
http://www.karger.com
Visit our mrsa / drug resistance section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/42901.php>
APA
http://www.medicalnewstoday.com/releases/42901.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



